The recent emergence of promising new candidate Alzheimer’s therapies has brought to light an urgent need to facilitate the diagnosis of the disease in its early stages when therapeutic intervention is most likely to deliver clinical benefit. While Alzheimer’s disease diagnostics often relies on a clinically based diagnoses of exclusion, biomarkers are playing an increasingly important role in the diagnostic journey. The Quanterix pTau-181 test is intended to be used in patients who are being evaluated for Alzheimer’s disease risk to aid in diagnostic evaluation. The Quanterix pTau- 181 assay is not a standalone diagnostic test. Download the whitepaper to learn more.